Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

Blood

Volumn 128, Issue 2, 2016, Pages 297-312

  Sekine, Takuya ^a   Marin, David ^a   Cao, Kai ^a   Li, Li ^a   Mehta, Pramod ^a   Shaim, Hila ^a   Sobieski, Catherine ^a   Jones, Roy ^a   Oran, Betul ^a   Hosing, Chitra ^a   Rondon, Gabriela ^a   Alsuliman, Abdullah ^a   Paust, Silke ^b   Andersson, Borje ^a   Popat, Uday ^a   Kebriaei, Partow ^a   Muftuoglu, Muharrem ^a   Basar, Rafet ^a   Kondo, Kayo ^a   Nieto, Yago ^a   Shah, Nina ^a   Olson, Amanda ^a   Alousi, Amin ^a   Liu, Enli ^a   Sarvaria, Anushruti ^a   Parmar, Simrit ^a   Armstrong James, Darius ^c   Imahashi, Nobuhiko ^a   Molldrem, Jeffrey ^a   Champlin, Richard ^a   Shpall, Elizabeth J ^a   Rezvani, Katayoun ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DS2; UNCLASSIFIED DRUG; HLA ANTIGEN;

ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BLOOD DONOR; CELL DIFFERENTIATION; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN CELL; K562 CELL LINE; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECIPIENT; RECURRENCE RISK; SURVIVAL; UMBILICAL CORD BLOOD; ALLOGRAFT; CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; GENOTYPING TECHNIQUE; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL RATE; UNRELATED DONORS;

ADULT; AGED; ALLOGRAFTS; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; RECEPTORS, KIR; SURVIVAL RATE; UNRELATED DONORS;

EID: 84978375312     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-706317     Document Type: Article

References (41)

1. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097-2100.
2. Savani BN, Rezvani K, Mielke S, et al. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2006;107(4):1688-1695.
3. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5): 495-502.
4. Yawata M, Yawata N, Draghi M, Partheniou F, Little AM, Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood. 2008; 112(6):2369-2380.
5. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-469.
6. Ljunggren HG, Kärre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today. 1990;11(7):237-244.
7. Winter CC, Long EO. A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J Immunol. 1997; 158(9):4026-4028.
8. Colonna M, Borsellino G, Falco M, Ferrara GB, Strominger JL. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- And NK2-specific natural killer cells. Proc Natl Acad Sci USA. 1993;90(24):12000-12004.
9. Moesta AK, Norman PJ, Yawata M, Yawata N, Gleimer M, Parham P. Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C than KIR2DL3. J Immunol. 2008;180(6): 3969-3979.
10. Marcenaro E, Pesce S, Sivori S, Carlomagno S, Moretta L, Moretta A. KIR2DS1-dependent acquisition of CCR7 and migratory properties by human NK cells interacting with allogeneic HLAC21 DCs or T-cell blasts. Blood. 2013;121(17): 3396-3401.
11. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436(7051):709-713.
12. Liao NS, Bix M, Zijlstra M, Jaenisch R, Raulet D. MHC class I deficiency: susceptibility to natural killer (NK) cells and impaired NK activity. Science. 1991;253(5016):199-202.
13. Anfossi N, André P, Guia S, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity. 2006;25(2):331-342.
14. Brodin P, Kärre K, Höglund P. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol. 2009;30(4):143-149.
15. Cooley S, Weisdorf DJ, Guethlein LA, et al. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood. 2010;116(14):2411-2419.
16. Venstrom JM, Pittari G, Gooley TA, et al. HLA-C dependent prevention of leukemia relapse by donor activating KIR2DS1. N Engl J Med. 2012; 367(9):805-816.
17. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood. 2003;102(3):814-819.
18. Rocha V, Labopin M, Sanz G, et al; Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22): 2276-2285.
19. Barker JN. Umbilical Cord Blood (UCB) transplantation: An alternative to the use of unrelated volunteer donors? Hematology Am. Soc. Hematol. Educ. Program. 2007:55-61.
20. Rocha V, Gluckman E. Outcomes of transplantation in children with acute leukaemia. Lancet. 2007;369(9577):1906-1908.
21. Marin D, Gabriel IH, Ahmad S, et al. KIR2DS1 genotype predicts for complete cytogenetic response and survival in newly diagnosed chronic myeloid leukemia patients treated with imatinib. Leukemia. 2012;26(2):296-302.
22. Saliba RM, Rezvani K, Leen A, et al. General and Virus-Specific Immune Cell Reconstitution after Double Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015;21(7):1284-1290.
23. Farag SS, Bacigalupo A, Eapen M, et al; KIR Study Group, Center for International Blood and Marrow Transplantation Research. The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: A report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. Biol Blood Marrow Transplant. 2006;12(8): 876-884.
24. Hsu KC, Gooley T, Malkki M, et al; International Histocompatibility Working Group. KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. Biol Blood Marrow Transplant. 2006; 12(8):828-836.
25. Stringaris K, Adams S, Uribe M, et al. Donor KIR Genes 2DL5A, 2DS1 and 3DS1 are associated with a reduced rate of leukemia relapse after HLAidentical sibling stem cell transplantation for acute myeloid leukemia but not other hematologic malignancies. Biol Blood Marrow Transplant. 2010;16(9):1257-1264.
26. Cooley S, Trachtenberg E, Bergemann TL, et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. Blood. 2009;113(3): 726-732.
27. Ebihara T, Jonsson AH, Yokoyama WM. Natural killer cell licensing in mice with inducible expression of MHC class I. Proc Natl Acad Sci USA. 2013;110(45):E4232-E4237.
28. Willemze R, Rodrigues CA, Labopin M, et al; Eurocord-Netcord and Acute Leukaemia Working Party of the EBMT. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009;23(3):492-500.
29. Schlegel P, Ditthard K, Lang P, et al. NKG2D Signaling Leads to NK Cell Mediated Lysis of Childhood AML. J.Immunol.Res. 2015;2015: 473175.
30. Feuchtinger T, Pfeiffer M, Pfaffle A, et al. Cytolytic activity of NK cell clones against acute childhood precursor-B-cell leukaemia is influenced by HLA class I expression on blasts and the differential KIR phenotype of NK clones. Bone Marrow Transplant. 2009;43(11):875-881.
31. Rouce RH, Shaim H, Sekine T, et al. The TGFb/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia. Leukemia. 2016;30(4): 800-811.
32. Sungur CM, Tang-Feldman YJ, Zamora AE, Alvarez M, Pomeroy C, Murphy WJ. Murine NKcell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. Blood. 2013;122(8):1518-1521.
33. Haas P, Loiseau P, Tamouza R, et al. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood. 2011;117(3):1021-1029.
34. Fischer JC, Kobbe G, Enczmann J, Haas R, Uhrberg M. The impact of HLA-C matching depends on the C1/C2 KIR ligand status in unrelated hematopoietic stem cell transplantation. Immunogenetics. 2012;64(12):879-885.
35. Leung W, Iyengar R, Turner V, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol. 2004;172(1):644-650.
36. Barker JN, Byam C, Scaradavou A. How I treat: The selection and acquisition of unrelated cord blood grafts. Blood. 2011;117(8):2332-2339.
37. Gluckman E, Rocha V, Arcese W, et al; Eurocord Group. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol. 2004;32(4):397-407.
38. Bradstock KF, Luxford C, Grimsley PG. Functional and phenotypic assessment of neonatal human leucocytes expressing natural killer cell-associated antigens. Immunol Cell Biol. 1993;71(Pt 6):535-542.
39. Gaddy J, Broxmeyer HE. Cord blood CD16156- cells with low lytic activity are possible precursors of mature natural killer cells. Cell Immunol. 1997; 180(2):132-142.
40. Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulinlike receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood. 2001;98(3):705-713.
41. Shah N, Martin-Antonio B, Yang H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013;8(10):e76781.\